TPG explores $5 billion sale of healthcare software company Lyric, sources say
Tap title to read story
Private equity firm TPG is exploring a potential five billion dollar sale of healthcare software provider Lyric, engaging investment bankers at JPMorgan Chase to manage the process. The company generates approximately two hundred fifty million dollars in annual earnings before interest, taxes, depreciation, and amortization, typically commanding a twenty times valuation multiple. Insurers including UnitedHealth Group, CVS Health, and Humana utilize Lyric to identify and prevent inaccurate medical claims payments. Originally acquired by TPG as ClaimsXten for two billion two hundred million dollars in 2022 to clear antitrust hurdles for UnitedHealth's acquisition of Change Healthcare, the business was rebranded in 2023. This exploratory sale highlights a broader recovery in software dealmaking following earlier market sell-offs driven by artificial intelligence disruption concerns. While TPG notes that Lyric has benefited from AI deployment, prospective buyers remain cautious about the long-term threat of cheaper, AI-native competitors disrupting established payment-integrity software.
More context
Timeline
- On 2022 exact date unverified TPG acquired ClaimsXten for two billion two hundred million dollars.
- On 2023 exact date unverified TPG officially rebranded the acquired claims software company as Lyric.
- On September 2025 public peer Claritev stock began tumbling significantly amid AI fears.
- On May 2026 public software peer Claritev stock hit its lowest point.
- On August 3 2026 Reuters published a standard corporate illustration of TPG.
- On September 9 2026 sources revealed TPG explored a sale for Lyric.
- On September 9 2026 Reuters reported that TPG hired JPMorgan for sales.
- On September 10 2026 Reuters updated reporting on the potential five billion valuation.
- In coming months prospective buyers will evaluate AI disruption risks for Lyric.
- In future quarters TPG and JPMorgan will determine transaction feasibility or withdrawal.
Why it matters
Immediate US impact: Private equity valuations face scrutiny over potential artificial intelligence disruption. Possible long-term US impact: Healthcare software valuations will hinge on adapting to native artificial intelligence. Most affected groups: Private equity firms, healthcare software providers, and major health insurers. Reader priority: Monitor financial news outlets for confirmed deal announcements or regulatory updates.
Coverage notes
Left: Highlighted regulatory scrutiny and corporate consolidation risks within healthcare. Center: Focused objectively on financial metrics, valuation multiples, and advisory roles. Right: Emphasized market recovery, private equity growth, and technological efficiency gains.
Primary report
Reuters published exclusive reporting regarding TPG exploring Lyric sale today.
Sources
JQJO Editorial Desk · Human reviewed · AI assisted. Report a correction.
